Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open‐label, phase 3 study

ABSTRACT Aims To compare the efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 (HS‐IDegAsp) with originator insulin degludec/insulin aspart‐Ryzodeg (NN‐IDegAsp) in Chinese patients with type 2 diabetes mellitus (T2DM) who were inadequately controlled on once‐ or twice‐daily (B...

Descripció completa

Dades bibliogràfiques

Autors principals:	Leili Gao, Zhifeng Cheng, Guoqing Ma, Xiaojun Cai, Xiaoyun Wang, Yibing Lu, Ziling Li, Wei Li, Shuping Zhao, Xuefeng Li, Chengwei Song, Yunming Gao, Jianlin Geng, Haiyan Cao, Jingfang Sun, Linong Ji
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2026-01-01
Col·lecció:	Journal of Diabetes Investigation
Matèries:	Biosimilar insulin Insulin degludec/insulin aspart Type 2 diabetes
Accés en línia:	https://doi.org/10.1111/jdi.70175
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!